Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 9/20 | 0.45 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CPT1A | P50416 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598527 | 0.79 | PDE4B (0.42) | PDE4BCPT1AKMT2AALDH1A1KDM4E | |
| SCHEMBL3580803 | 0.79 | PDE4B (0.42) | PDE4BCPT1AKMT2AALDH1A1KDM4E | |
| SCHEMBL13198801 | 0.78 | SHMT2 (0.43) | PDE4BSHMT2POLBKMT2AALDH1A1 | |
| SCHEMBL3587243 | 0.77 | KMT2A (0.44) | KMT2AALDH1A1KDM4EMEN1HPGD | |
| SCHEMBL2953761 | 0.73 | KMT2A (0.37) | PDE4BSHMT2KMT2AALDH1A1KDM4E | |
| SCHEMBL4501356 | 0.72 | POLB (0.49) | POLBKMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL4501351 | 0.72 | POLB (0.49) | POLBKMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL4501347 | 0.72 | POLB (0.49) | POLBKMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL3585634 | 0.72 | ROCK1 (0.42) | KMT2AALDH1A1KDM4EMEN1HPGD | |
| SCHEMBL3585639 | 0.72 | ROCK1 (0.42) | KMT2AALDH1A1KDM4EMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825112-B2 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | disclosed |
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PKD2, QPCT, CCNT2 | PDE4B 267/4885SHMT2 1580/4885POLB 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.